Dynashield, a 4 oz cream, is recalled after cGMP deviations were identified. The recall affects 7,944 units distributed nationwide. Consumers should stop using the product immediately and contact their healthcare provider for guidance.
cGMP deviations
Consumers and healthcare providers should stop using this product immediately. Contact Blossom Pharmaceuticals or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Dynashield cream, 4 oz (113 g), manufactured for Dynarex Corporation. Lot numbers include A092421, A092340, A092346. Distributed nationwide in the USA.
The cream has been found to have deviations from current Good Manufacturing Practices (cGMP). Such issues may affect the product's safety and efficacy.
No specific injuries or incidents have been reported at this time. The recall is precautionary due to manufacturing deviations.
Stop using Dynashield cream immediately. Contact Blossom Pharmaceuticals or your healthcare provider for further guidance. Notification will be sent via letter.
For more information, visit the FDA recall page at https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=D-0207-2026.
Get instant alerts for recalls that affect you. Free forever.
Failed Dissolution Specifications: This recall has been initiated due to an Out of Specification finding in dissolution.
Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for weight-adjusted infusion.
Lack of Assurance of Sterility: due to the presence of particulate matter in one unit from the lot, which lab tests have identified as wool fiber.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Software anomaly in the patient positioning system may result in positional discrepancy.
Software anomaly in the patient positioning system may result in positional discrepancy.
Customer complaints report low to no recovery of Campylobacter Jejuni ATCC 33291 on identified lot of medium.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.